|
E1: complainant street address: (b)(6).Based on the available information, this event is deemed to be a reportable malfunction.To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number reporting site: 1049092 manufacturing site: 1000317571.
|
|
Additional information - this emdr is being submitted to include the below: h4: device manufacture date h6: investigation results under type of investigation, investigation findings, investigation conclusions.H11: investigation summary, based on the available information, this event is deemed to be a reportable malfunction.Complaint malfunction was received from the philippines reporting foreign matter (¿dirty dressing¿) on one unit of kaltostat drs 7.5x12cm (system application product (sap) 1703039, lot 4k04783).The batch was manufactured on 27-oct-2024 and sterilized under certificate 2173-51674a by steris on 09-nov-2025.Total batch size was 6,030 secondary packs ((b)(4)primary units).Affected amount: 1 primary pack (01 devices).Two photographs were provided and reviewed in accordance with work instruction (wi).The product and lot number were confirmed.The observed material was identified as excess kaltostat fiber, an inherent process by-product, and not foreign matter contamination.No physical sample was returned for further analysis.The complaint is therefore confirmed as meets specification and does not represent true contamination.A full batch record review was completed.All in-process checks, stat samples, and final release inspections were acceptable.No discrepancies, deviations, or non-conformances were identified.Sterilization results were within specification and approved by steris prior to release.Trend review identified no other complaints of this nature for lot 4k04783.Other unrelated complaints (damage to outer pack, short count) have been recorded, and one similar case (brown/dusty fiber confirmed as process fiber) was reported on a different lot.No systemic pattern or recurrence is evident.The risk assessment concluded there is no impact to product traceability, function, sterility, or patient safety.The observation is cosmetic only.According to process instruction (pi), the acceptable quality level (aql) for contamination is 0.40 (accept at 2, reject at 3 based on 200-unit sample for a batch size of 6,030 secondary packs).With one unit affected and no further complaints, the lot remains within acceptable quality limits.In accordance with work instruction (wi) section 6.1.4, no new corrective and preventive actions (capa) is required.The event is considered isolated and will be monitored through routine complaint trending and the post market product monitoring review process standard operating procedure (sop).To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number: reporting site: 1049092.Manufacturing site: 1000317571.
|